Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Patient is an ambulatory postmenopausal woman - Patient has BMD value that corresponds to a T-score of less than or equal to -2.0 (g/cm2) at the lumbar spine OR total hip within range specific to the study protocol. Exclusion Criteria: o Any disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures~* Evidence of any of the following per subject report, chart review or central laboratory result:~  1. Hyper- or hypothyroidism; however, subjects on stable thyroid hormone replacement therapy may be allowed per the following criteria:~     * If TSH level is normal, subject is eligible for the study.~    * If TSH level is below normal range, subject is not eligible for the study.~    * If TSH level is elevated (\> 5.5 mIU/mL to 10.0 mIU/mL), serum T4 should be measured. If serum T4 is within normal range, subject is eligible. If serum T4 is outside of normal range, subject is not eligible for the study.~    * If TSH level is above 10.0 mIU/mL, subject is not eligible.~ 2. Current hyper- or hypoparathyroidism~ 3. Elevated transaminases~     * Serum aspartate aminotransferase (AST; serum glutamate-oxaloacetic transaminase \[SGOT\]) ³ 2.0 x upper limits of normal (ULN)~    * Serum alanine aminotransferase (ALT; serum glutamate-pyruvate transaminase \[SGPT\]) ³ 2.0 x ULN~ 4. Significantly impaired renal function as determined by serum creatinine ³ 2.0 mg/dL~ 5. Current hypo- or hypercalcemia based on the central laboratory reference ranges~ 6. Active gastric or duodenal ulcer; history of significant gastrointestinal bleed requiring hospitalization or transfusion, or dyspepsia or gastroesophageal reflux disease that is uncontrolled by medication~ 7. Rheumatoid Arthritis, Paget's disease, Cushing's disease, hyperprolactinemia, or cirrhosis of the liver~ 8. Known to have tested positive for human immunodeficiency virus, hepatitis C virus, or hepatitis B surface antigen~ 9. Malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years~ 10. Any metabolic bone disease, eg, osteomalacia or osteogenesis imperfecta, which may interfere with the interpretation of the findings~ 11. Malabsorption syndrome or any gastrointestinal disorders that are associated with malabsorption~* Received any solid organ or bone marrow transplant~* Vitamin D deficiency (25(OH) vitamin D level \< 12 ng/mL). Vitamin D repletion will be permitted and subjects may be re-screened; see Section 7.~* Any laboratory abnormality which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results~* Contraindicated or poorly tolerant of ALN therapy; contraindications for ALN therapy include:~  1. Abnormalities of the esophagus, which delay esophageal emptying such as stricture or achalasia.~ 2. Inability to stand or sit upright for at least 30 minutes.~ 3. Hypersensitivity to ALN or other constituents of ALN tablets o Known sensitivity to mammalian cell derived drug products~* Known intolerance to calcium supplements~* Administration of intravenous bisphosphonate, or fluoride (except for dental treatment) or strontium ranelate~* Oral bisphosphonate treatment:~  * ³ 3 months cumulatively in the past 2 years, OR~ * ³ 1 month in the past year, OR~ * Any use during the 3-month period prior to randomization~* PTH or PTH derivatives (eg, teriparatide) within the last year~* Administration of any of the following treatments within 3 months of randomization:~  1. Any SERM (eg, raloxifene)~ 2. Tibolone~ 3. Anabolic steroids or testosterone~ 4. Glucocorticosteroids (³ 5 mg prednisone equivalent per day for more than 10 days)~ 5. Systemic (oral, transdermal, topical) hormone replacement therapy (local vaginal estrogen preparation will be allowed)~ 6. Calcitonin~ 7. Calcitriol or vitamin D derivatives~ 8. Other bone active drugs including anti-convulsives (except benzodiazepines) and heparin~ 9. Chronic systemic ketoconazole, androgens, ACTH, cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, gonadotropin-releasing hormone agonists~ 10. Height, weight or girth which may preclude accurate DXA measurements~* Less than 2 lumbar vertebrae (L1-L4) evaluable for DXA measurements~* Both hips not evaluable by DXA (eg, history of bilateral hip replacement or pins in both hips)~* Currently enrolled in or has not yet completed at least 1 month since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s)~* Any physical or psychiatric disorder which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results~* Evidence of alcohol or substance-abuse within the last 12 months which the investigator believes would interfere with understanding or completing the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alendronate (Type: ACTIVE_COMPARATOR): Subjects in this arm will receive active ALN and placebo denosumab
- Denosumab (Type: EXPERIMENTAL): Subjects in this arm will receive active denosumab and placbo ALN

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete